Condition
Overweight or Obesity
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 152 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808 · 2026-07-28
RECRUITINGTesting Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight RegainNCT07708064 · 2026-07-14
RECRUITINGSafety and Drug Concentrations of REGN20934 in Adults With Overweight or ObesityNCT07594093 · 2026-06-29
RECRUITINGMetformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic EvaluationNCT07654179 · 2026-06-17
RECRUITINGEffect of the Thrive AI Health App on Lifestyle Behaviors and Quality of LifeNCT07376655 · 2026-06-04
RECRUITINGEfficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 · 2026-02-09
RECRUITINGExtension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossNCT07292441 · 2026-01-22
RECRUITINGA Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese ParticipantsNCT07294235 · 2025-12-05
RECRUITINGRelative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight SubjectsNCT07150962 · 2025-10-15
RECRUITINGEvaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and WomenNCT07224399 · 2025-10-09
RECRUITINGAcute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain HealthNCT06953232 · 2025-09-30
RECRUITINGThe Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive ImpairmentNCT07395960 · 2025-09-01
RECRUITINGHealthy Living BEYOND Weight StudyNCT07075341 · 2025-06-30
RECRUITINGA Study to Evaluate MWN109 Tablets in Healthy Adult ParticipantsNCT06938269 · 2025-06-18
RECRUITINGWeight Reduction in CLBPNCT04824248 · 2025-05-01
RECRUITINGA Study of HS-20094 in Overweight or Obese ParticipantsNCT07057674 · 2025-04-16
RECRUITINGSemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial FibrillationNCT06499857 · 2025-04-14
RECRUITINGeMOTION: Examining Implicit Attitudes in Physical Activity EngagementNCT07044570 · 2025-03-24
RECRUITINGA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942 · 2025-03-19
RECRUITINGThe Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and ObesityNCT06830343 · 2025-02-27
RECRUITINGCraving Network NeurofeedbackNCT06426693 · 2024-11-27
RECRUITINGA Study of BGM0504 Injection in Participants with Obesity or OverweightNCT06704581 · 2024-10-28
RECRUITINGThe Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery DiseaseNCT06606821 · 2024-10-01
RECRUITINGeMOTION: Examining Affective Mechanisms in Physical Activity EngagementNCT06570642 · 2024-08-14
RECRUITINGA Study to Evaluate Features of KN069 in Participants With Obesity or OverweightNCT06547775 · 2024-08-02
RECRUITINGThe Acute T-Rex (Timing of Resistance Exercise) StudyNCT06366399 · 2023-11-15
RECRUITINGLifestyle Intervention in Overweight/Obese Chronic Low Back Pain (CLBP) Patients: an International Multi-center RCTNCT05811624 · 2023-04-13
RECRUITINGNDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes RisksNCT05674799 · 2023-04-08
RECRUITINGTaxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)NCT05770570 · 2022-12-22
RECRUITINGBetter Lifestyle Counseling for African American Women During PregnancyNCT05234125 · 2022-08-16
RECRUITINGCommunity Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort StudyNCT06596265 · 2016-02-17
RECRUITINGA Study of SYH2092 Injection in Healthy ParticipantsNCT07776041 · 2026-09-30
NOT_YET_RECRUITINGEfficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.NCT07803991 · 2026-09-01
NOT_YET_RECRUITINGA Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in ObesityNCT07690826 · 2026-07-01
NOT_YET_RECRUITINGA Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932 · 2026-05-11
ACTIVE_NOT_RECRUITINGA Single Ascending Dose Study of SYH2082 Injection in Healthy ParticipantsNCT07532655 · 2026-04-14
NOT_YET_RECRUITINGA Study of SYH2082 Injection in Healthy ParticipantsNCT07736404 · 2026-04-13
ACTIVE_NOT_RECRUITINGA Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or OverweightNCT07499050 · 2026-03-30
ACTIVE_NOT_RECRUITINGRemotely Delivered Resistance Training for Cardiometabolic Health Among Black WomenNCT06360536 · 2026-03-19
ACTIVE_NOT_RECRUITINGStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086 · 2026-03-16
ACTIVE_NOT_RECRUITINGA Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）NCT07274137 · 2026-02-01
NOT_YET_RECRUITINGA Study of SYH2069 Injection in Healthy ParticipantsNCT07736391 · 2026-01-10
ACTIVE_NOT_RECRUITINGA Study of IBI3032 in Chinese Participants With Overweight or ObesityNCT07170319 · 2025-09-25
ACTIVE_NOT_RECRUITINGEfficacy of Satisens® in Reducing Emotional EatingNCT07079046 · 2025-09-15
COMPLETEDA Study of LY4064912 in Healthy Participants and With Overweight or ObesityNCT07152002 · 2025-08-28
TERMINATEDEffectiveness of a Digital Behavioral Intervention Program for Overweight and Obese PatientsNCT07045272 · 2025-07-10
NOT_YET_RECRUITINGA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · 2025-04-30
ACTIVE_NOT_RECRUITINGThe Effect of AMG 133 on Gastric EmptyingNCT07429032 · 2025-04-17
COMPLETEDEffect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)NCT06845345 · 2025-04-14
ENROLLING_BY_INVITATIONA Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightNCT06973720 · 2025-04-07
ACTIVE_NOT_RECRUITINGPylorus Distensibility MeasurementNCT06908551 · 2025-04-01
NOT_YET_RECRUITINGA Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or ObesityNCT06854952 · 2025-03-07
COMPLETEDA Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026 · 2025-03-06
ACTIVE_NOT_RECRUITINGAn Innovative Care Model Integrating Mobile Health Support to Promote Weight Management in Adults With Overweight or ObesityNCT06996431 · 2025-02-10
ENROLLING_BY_INVITATIONA Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy SubjectsNCT06762600 · 2025-01-16
COMPLETEDEffect of Psiguavin for Obesity Treatment (PSIGUAVIN)NCT06512818 · 2025-01-08
ENROLLING_BY_INVITATIONA Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese SubjectsNCT06621316 · 2024-10-30
COMPLETEDA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · 2024-10-22
COMPLETEDEffect of Akkermansia Muciniphila Akk11 on Metabolic and Gut Health in Overweight and Obese SubjectsNCT06653101 · 2024-10-20
COMPLETEDA Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or OverweightNCT06712836 · 2024-10-09
COMPLETEDCommon interventions
PlaceboDRUG40HRS9531 injectionDRUG4OrforglipronDRUG4SemaglutideDRUG4HRS9531 injection PlaceboDRUG3PlaceboDIETARY_SUPPLEMENT3PlaceboOTHER3SAVOR EnhancementBEHAVIORAL3TirzepatideDRUG3TYPE/CONTEXT enhancementBEHAVIORAL3AcetaminophenDRUG2BGM1812DRUG2ControlDIETARY_SUPPLEMENT2ControlOTHER2HRS-4729 InjectionDRUG2HRS-4729 injection placeboDRUG2MET097DRUG2OlatorepatideDRUG2Physical activityBEHAVIORAL2Physical Activity Goals mHealth InterventionBEHAVIORAL2ProbioticDIETARY_SUPPLEMENT2PropofolDRUG2remimazolamDRUG2SYH2069 InjectionDRUG2SYH2082 InjectionDRUG2
Leading sponsors
Eli Lilly and Company
10
Fujian Shengdi Pharmaceutical Co., Ltd.
6
University of Chicago
4
Yale University
4
BrightGene Bio-Medical Technology Co., Ltd.
3
Clinical Nutrition Research Center, Illinois Institute of Technology
3
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
3
CSPC Ouyi Pharmaceutical Co., Ltd.
3
Empros Pharma AB
3
Pfizer
3
Regeneron Pharmaceuticals
3
University of Southern California
3
Beijing QL Biopharmaceutical Co.,Ltd
2
Green Beat
2
Novo Nordisk A/S
2
Trial status mix
COMPLETED69
RECRUITING31
ACTIVE_NOT_RECRUITING19
UNKNOWN16
NOT_YET_RECRUITING7
ENROLLING_BY_INVITATION4
TERMINATED3
WITHDRAWN3
Phase mix
NA71
PHASE129
PHASE227
PHASE314
PHASE46
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.